A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

NCT01472198 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Simtuzumab
DRUG: Gemcitabine
DRUG: Placebo to match simtuzumab

Sponsor

Gilead Sciences